Bvf Inc Blueprint Medicines Corp Transaction History

Bvf Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $8.84 Million - $15.1 Million	-183,834 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $16.9 Million - $21 Million	-253,731 Reduced 57.99%	183,834 $14.7 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $9.37 Million - $12.5 Million	-127,400 Reduced 22.55%	437,565 $41.3 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $487,097 - $866,173	-10,002 Reduced 1.74%	564,965 $45.2 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $1.06 Million - $1.73 Million	-23,300 Reduced 3.89%	574,967 $31 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $2.86 Million - $3.8 Million	-48,544 Reduced 7.51%	598,267 $46.7 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $536,448 - $890,384	-8,800 Reduced 1.34%	646,811 $41.1 Million
Q1 2018 May 07, 2018	SELL	$73.28 - $102.95 $8.19 Million - $11.5 Million	-111,743 Reduced 14.56%	655,611 $60.1 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $15.1 Million - $21.2 Million	-240,000 Reduced 23.82%	767,354 $57.9 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $42.7 Million - $70.2 Million	1,007,354	1,007,354 $70.2 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.